XORTX Appoints Chief Financial Officer
August 04 2023 - 4:00PM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to announce the appointment of James Fairbairn
as Chief Financial Officer to replace Amar Keshri who left the
Company’s employ effective July 31, 2023. James Fairbairn was
appointed Interim Chief Financial Officer on June 28, 2023.
James Fairbairn was the Company’s Chief
Financial Officer from November 2018 through July 2021. He has more
than 30 years of experience with publicly-traded companies. He is a
Chartered Professional Accountant, having obtained his CPA
designation in 1987 and is an Institute-certified Director. Jim
Fairbairn holds a B.A. from Western University.
About XORTX
Therapeutics Inc.XORTX is a pharmaceutical company with
two clinically advanced products in development: 1) our lead,
XRx-008 program for ADPKD; and 2) our secondary program in XRx-101
for acute kidney and other acute organ injury associated with
Coronavirus / COVID-19 infection. In addition, XRx-225 is a
pre-clinical stage program for Type 2 Diabetic Nephropathy. XORTX
is working to advance its clinical development stage products that
target aberrant purine metabolism and xanthine oxidase to decrease
or inhibit production of uric acid. At XORTX, we are dedicated to
developing medications to improve the quality of life and future
health of patients. Additional information on XORTX is available at
www.xortx.com.
For more information, please contact: |
|
|
|
Allen Davidoff,
CEOadavidoff@xortx.com or +1 403 455 7727 |
Nick Rigopulos, Director of
Communicationsnick@alpineequityadv.com or +1 617 901 0785 |
|
|
Media Inquiries,
David Melamed, Ph.D.david.melamed@russopartnersllc.com or +1
212 845 4225 |
|
|
Neither the TSX
Venture Exchange nor Nasdaq has approved or disapproved the
contents of this news release. No stock exchange, securities
commission or other regulatory authority has approved or
disapproved the information contained herein.
Forward Looking StatementsThis
press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of XORTX only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Except as otherwise required by law,
XORTX undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated
events. More detailed information about the risks and uncertainties
affecting XORTX is contained under the heading “Risk Factors” in
XORTX’s Registration Statement on Form F-1 filed with the SEC,
which is available on the SEC's website, www.sec.gov (including any
documents forming a part thereof or incorporated by reference
therein), as well as in our reports, public disclosure documents
and other filings with the securities commissions and other
regulatory bodies in Canada, which are available on
www.sedar.com.
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From Apr 2024 to May 2024
XORTX Therapeutics (NASDAQ:XRTX)
Historical Stock Chart
From May 2023 to May 2024